Detection Technologies
Stephen Lundy of Venaxis Inc. (formerly AspenBio Pharma) Any parent who has rushed to Urgent Care with a toddler shrieking in abdominal pain will appreciate the big opportunity Stephen Lundy saw when he became head of Venaxis Inc. (formerly AspenBio Pharma). A 25-year veteran of the IVD industry, Lundy says the market potential of the appendicitis blood test that the company was developing lured him from his CEO post at MicroPhage to Venaxis’s Colorado headquarters. When Lundy...
Image: Lumora Ltd. Recent updates to HIV treatment guidelines have revealed a trend toward earlier treatment and highlighted the longer life expectancy being seen in the HIV population.1-3 Collectively, these two factors mean that patients are receiving antiretroviral therapy (ART) for longer than ever before. In the developing world, efforts to scale up treatment of HIV have led to increases in the proportion of patients receiving combination ART (cART).4 However, in areas where...
  Shopping for parts, components, services, and new technologies at the Clinical Lab Expo next week? You're in luck. Here's just a tiny sampling of what will be on display there. Isolation Miniature Valves Solenoid-operated valves use a flexible diaphragm to isolate the solenoid actuation mechanism from the fluid path. When the valve is energized, the solenoid retracts an armature that is attached to a flexible diaphragm. In a normally closed valve, this raises the diaphragm, allowing...
The Clinical Lab Expo will feature new science and technology in every area of clinical diagnostics, automation, information systems, point of care, OEM, and biotech. Roughly 750 organizations will occupy about 2000 booths. According to Clinical Lab Expo's Website, "You will see more products in every clinical lab discipline than at any other show." Find What You Need The Clinical Lab Expo will have special sections for special products. Visit the special sections for point-of-...
Last December, PwC released a new report, “Diagnostics 2011: M&A Surges, Companion Diagnostics Accelerate, and Early Detection Offers New Prospects.” This report provides an overview of merger and acquisition deal activity in the IVD industry during the past two years and the factors driving it, an assessment of the development of new prospects for early detection testing, and a review of significant events for the development of personalized medicine. The report also...
A company offers six new highly characterized seroconversion panels for current assay qualification. The HIV seroconversion panels feature enhanced product information, including Fiebig stage and fourth-generation screening-test results. Each panel consists of a set of undiluted plasma samples from a single plasma donor during a period of HIV seroconversion, and is ready to use in vials of 1.0 ml per patient sample. Data sheets for each panel list results from twenty U.S. and international test...
In the field of detection technology, advances in multiplexing and the increasing emphasis on point of care are of primary importance. Trends include nonenzymatic and isothermal approaches for nucleic-acid testing, which reduce the complexity of very complicated molecular assays. The primary challenge right now is the front-end automation: sample acquisition and preparation. To learn more about what’s new in detection technology, IVD Technology editor Richard Park spoke with John C....
An article on detection technologies that was previously published in IVD Technology’s 10th anniversary issue covered the more traditional means of developing assays that had already been commercialized and used for some time.1 That article also covered matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) technology in order to show some of the newer techniques for protein detection in human plasma and its use in tissue imaging (e.g., detection of cancerous tissues...
Most immunodiagnostic and nucleic acid detection methods have in common the use of a solid surface onto which a bioactive reagent is coated, such as an antibody, antigen, or oligomeric probe. Such biomolecules are complex long-chain structures possessing optimal three-dimensional conformation with specific loci for binding sites or epitopes. However, the conventional deposition of bioactive molecules onto solid surfaces is an inefficient and random process. For example, while antibodies can...
With the promise of personalized medicine and effective targeted molecular therapeutics on the horizon, developing translational IVDs that can accurately select patients for specific therapies or treatment regimens has become more critical. Two of the best known examples in oncology are the examination of estrogen receptors and HER2 expression using immunohistochemistry (IHC) to predict the response to tamoxifen and Herceptin, respectively (see Figure 1). As a measurement of expression in fixed...